Clinical trial · Interventional
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
An Open-label, Multicenter Rollover Study to Provide Continued Treatment With Anetumab Ravtansine for Participants With Solid Tumors Who Were Enrolled in Previous Bayer-sponsored Studies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Due to strategic company decisions, the development of anetumab ravtansine was stopped.
Summary
Brief summary (as posted)
The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BAY94-9343 (Anetumab ravtansine) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Cancer patients
- description
- Adult patients with solid cancer who received anetumab-ravtansine treatment in a completed Bayer study
- interventionNames
- Drug: BAY94-9343 (Anetumab ravtansine)
Primary outcomes (1)
- measure
- Number of Participants With TEAEs, TESAEs and Drug-related TEAEs and TESAEs
- timeFrame
- Approximately 3 years (from first study treatment until safety follow-up)
- description
- Treatment emergent adverse events (TEAEs) were defined as AEs starting or worsening during the treatment period. The treatment period extended from the first date of study treatment in this study until the safety follow-up (30 days after the last administration of study treatment). TESAEs: Treatment emergent serious adverse events.
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants ongoing in an applicable Bayer-sponsored anetumab ravtansine parent study at the time of its planned study closure. * For on-treatment participants: participant is eligible to receive the next dose of study intervention per the parent study protocol. * For on-treatment participants: any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption. For applicable studies: should treatment be permanently interrupted in the parent study, participants may be enrolled in the follow-up portion of the rollover study. Exclusion Criteria: * For on-treatment participants: a positive serum pregnancy test. * For on-treatment participants: use of one or more of the prohibited medications listed in the respective parent study protocol. * Participants who are receiving standard-of-care agent(s) but not anetumab ravtansine in the parent study, and are able to receive standard-of-care agent outside of the clinical study.
References
Publications (0)
Data not yet available